Rakesh Popat

Optimizing oncology drug development: systematic review of 22 years of myeloma gerandomiseerde controlled trials.

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including totale overleving ...

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma:...

A phase 2 gerandomiseerde study of modakafusp alfa as a single agent for patiënten met relapsed/refractory multiple m...

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple ...

Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BE...

Immunotherapie bij myeloom: IMWG consensusrichtlijnen 2024

Cilta-cel versus standaard bij lenalidomide-refractair myeloom: CARTITUDE-4 fase III

ASCT versus KCd onderhoud bij myeloom: NCT02816684 fase II

Venetoclax plus bortezomib-dexamethason versus placebo plus Vd bij recidief myeloom: BELLINI fase III

Belantamab mafodotin bij recidief/refractair myeloom: DREAMM-2 fase II